Effects of Oral Ingestion of Drinking Water Using a Tumbler That Emits Far Infrared Rays at Room Temperature on Metabolic Profile in Adults: a RCT
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Metabolic Problems
- Sponsor
- Pusan National University Yangsan Hospital
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Low density lipoprotein cholesterol (LDL-C)
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of oral ingestion of drinking water using a tumbler that emits far infrared rays at room temperature on metabolic profile in adults for 8 weeks.
Detailed Description
The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of oral ingestion of drinking water using a tumbler that emits far infrared rays at room temperature on metabolic profile in adults for 8 weeks; the safety of the compound are also evaluate. The Investigators examine lipid profile, glucose, liver and renal function at baseline, as well as after 4, 8 weeks of intervention. Thirty adults were administered either 1.8 L of drinking water using a tumbler that emits far infrared rays at room temperature or drinking water using a sham-tumbler each day for 12 weeks.
Investigators
Sang Yeoup Lee
Professor of Family Medicine
Pusan National University Yangsan Hospital
Eligibility Criteria
Inclusion Criteria
- •19 years and older
Exclusion Criteria
- •aspartate aminotransferase (AST) or alanine aminotransferase (ALT) more than twice the highest reference value
- •serum creatinine ≥ 1.5 mg/dL)
- •uncontrolled diabetes mellitus (a fasting glucose of \>160 mg/dL)
- •uncontrolled hypertension (BP \> 160/100 mmHg)
- •severe gastrointestinal symptoms
- •alcohol abuser
- •pregnant or lactating women
- •allergic to the ingredient involved
- •cardiocebrovascular diseases or any cancer during the six months prior to study
Outcomes
Primary Outcomes
Low density lipoprotein cholesterol (LDL-C)
Time Frame: Change from baseline level of LDL-C at 8 weeks
Change of LDL-C during 8 weeks
Secondary Outcomes
- creatinine(Change from baseline level of creatinine at 8 weeks)
- body weight(Change from baseline level at 8 weeks)
- aspartate transaminase (AST)(Change from baseline level of AST at 8 weeks)
- free fatty acid(Change from baseline level at 8 weeks)
- homeostasis model assessment of insulin resistance (HOMA-IR)(Change from baseline level of HOMA-IR at 8 weeks)
- alanine transaminase (ALT)(Change from baseline level of ALT at 8 weeks)